Conflict of interest: Nothing to report.
THSNA Meeting Proceedings
Reversal of antithrombotic agents†
Version of Record online: 28 MAR 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 87, Issue S1, pages S119–S126, May 2012
How to Cite
Bauer, K. A. (2012), Reversal of antithrombotic agents. Am. J. Hematol., 87: S119–S126. doi: 10.1002/ajh.23165
- Issue online: 19 APR 2012
- Version of Record online: 28 MAR 2012
- Accepted manuscript online: 24 FEB 2012 07:39AM EST
- Manuscript Accepted: 14 FEB 2012
- Manuscript Revised: 9 FEB 2012
- Manuscript Received: 27 DEC 2011
- Bayer HealthCare Pharmaceuticals
- Janssen Research and Development and LLC
Anticoagulants are the mainstay of therapy for thromboembolic diseases. In addition to the more traditional agents, new oral anticoagulants, including dabigatran etexilate, rivaroxaban, and apixaban, have been shown to be effective across several indications. Bleeding is a serious complication associated with any anticoagulant, but many of the traditional parenteral and new oral agents do not currently have specific antidotes. This review describes available and future options for the reversal of the effects of anticoagulants, in particular the new oral agents and discusses current management strategies for bleeding events in clinical practice. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.